Cerebral Toxoplasmosis in a Treatment Naive HIV Patient with High CD4 Count Responding to Treatment with a Regime of Cotrimoxazole and Pyrimethamine: Do We Need to Start Prophylaxis for Toxoplasmosis at a Higher CD4 Count?
DOI:
https://doi.org/10.17140/HARTOJ-2-111Keywords:
Cerebral toxoplasmosis, Opportunistic infections, HAART, Cotrimoxazole, IgG: Immunoglobulin G, ELISA: Enzyme-linked immunosorbent assayAbstract
Cerebral toxoplasmosis is one of the commonest opportunistic infection of the nervous system in HIV patients. We present a case of gradual onset haemiparesis in an ART naïve HIV patient with high CD4 count who was subsequently diagnosed to be a case of cerebral toxoplasmosis based on radiological and serological investigations. The patient responded to a regime of Cotrimoxazole and Pyrimethamine. His CD4 count at diagnosis was 299/µl. HAART was started after completion of treatment of cerebral toxoplasmosis. Prophylaxis against toxoplasmosis is recommended with cotrimoxazole if the CD4 count is below 200/µl. However, in this case as the patient had developed toxoplasmosis at a CD4 count value above the cut-off value for prophylaxis for cerebral toxoplasmosis, it may be worth considering to starting prophylaxis at a higher CD4 count than 200/µl and continuing for a longer time than the current guidelines.
References
Pereira-Chioccola VL, José Ernesto L, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected Pa-tients. Future microbiol. 2009; 4(10): 1363-1379. doi: 10.2217/ fmb.09.89
Vidal JE, Hernandez AV, Penalva de Oliveira AC, et al. Ce-rebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDs. 2005; 19: 626-634. doi: 10.1089/ apc.2005.19.626
Gaspar G, Monereo A, Barros C, et al. Incidence of first epi-sodes of HIV: opportunistic diseases and its changes over time in the period 1987-2001 in the COMESEM Cohort Study. Pre-sented at 14th International AIDS Conference. Barcelona, Spain. 2002.
Mohraz M, Mehrkhani F, Jam S, et al. Seroprevalence of toxoplasmosis in HIV(+)/AIDS patients in Iran. Acta Med Iran. 2011; 49(4): 213-218.
Luma NH, Benjamin Tchaleu BC, Mapoure YN, et al. Toxo-plasma encephalitis in HIV/AIDS patients admitted to the Doua-la general hospital between 2004 and 2009: a cross sectional study. BMC Research Notes. 2013, 6: 146. doi: 10.1186/1756- 0500-6-146
Mayor AM, Santos DMF, Dworkin MS, Ríos-Olivares E, Hunter-Mellado RF. Toxoplasmic Encephalitis in an AIDS Co-hort at Puerto Rico before and after Highly active antiretroviral therapy (HAART). Am J Trop Med Hyg. 2011; 84(5): 838-841. doi: 10.4269/ajtmh.2011.10-0718
Nascimento LV, Stollar F, Tavares LB, et al. Risk factors for toxoplasmic encephalitis in HIV-infected patients: a case-con-trol study in Brazil. Ann Trop Med Parasitol. 2001; 95(6): 587- 593. doi: 10.1080/00034980120073931
Khan A, Su C, German M, et al. Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J Clin Microbiol. 2005; 43: 5881- 5887. doi: 10.1128/JCM.43.12.5881-5887.2005
Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous sys-tem infections in individuals with HIV-1 infection. J Neurovirol. 2002; 8: 158-167.
CDC. Guidelines for the prevention and treatment of oppor-tunistic infections in HIV-infected adults and adolescents. Rec-ommendations from the Centers for Disease Control and Pre-vention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Web-site: http://www.guideline.gov/content.aspx?id=45359 2009; Accessed April 10, 2009.
Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A random-ized trial comparing pyrimethamine plus clindamycin to py-rimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann. Intern. Med. 1992; 116(1): 33-43. doi: 10.7326/0003-4819-116-1-33
Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS. 1996; 10(10): 1107-1112.
Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine–sulfa-diazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob. Agents Chemother. 1998; 42: 1346-1349.
Dedicoat M, Livesley N. Management of toxoplasmic en-cephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst. Rev. 2006; 19(3): CD005420. doi: 10.1002/14651858.CD005420.pub2
Béraud G, Pierre-François S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg. 2009; 80(4): 583- 587.
Derouin, F, , Jacqz-Aigrain E, Thulliez P, s Couvreur J, Le-port C. Cotrimoxazole for Prenatal Treatment of Congenital Toxoplasmosis? Parasitology Today. 2000; 16(6): 254-256.
Centers for Disease Control and Prevention, the National In-stitutes of Health, and the HIV Medicine Association of the In-fectious Diseases Society of America. Guidelines for the preven-tion and treatment of opportunistic infections in HIV-infected adults and adolescents.
Mocroft A, Furrer HJ, Miro JM, et al. Opportunistic infec-tions working group on behalf of the collaboration of observa-tional hiv epidemiological research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination anti-retroviral therapy era. Clin Infect Dis. 2013; 57(7): 1038-1047. doi: 10.1093/cid/cit423
Fournier S, Rabian C, Alberti C, et al. Immune recovery un-der highly active antiretroviral therapy is associated with resto-ration of lymphocyte proliferation and interferon-g production in the presence of toxoplasma gondii antigens. The Journal of In-fectious Diseases. 2001; 183: 1586-1591. doi: 10.1086/320706
Antinori A, Larussa D, Cingolani A, et al. Prevalence, as-sociated factors, and prognostic determinants of aids-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Oxford Journals Medicine & Health Clinical Infectious Diseases. 2004; 39(11): 1681-1691. doi: 10.1086/424877
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
